Cecile Deleine
Nantes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer.
Journal: Molecular therapy. Oncology
Published: January 28, 2026
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.
Journal: Oncoimmunology
Published: July 10, 2024
Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy.
Journal: Cancers
Published: August 04, 2022
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Journal: Oncoimmunology
Published: March 17, 2022
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Journal: Oncoimmunology
Published: July 09, 2021
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
Journal: Biology
Published: February 18, 2021
The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.
Journal: Cancers
Published: November 30, 2020
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Journal: Journal for immunotherapy of cancer
Published: January 05, 2020
The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: March 28, 2019
The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.
Journal: Oncoimmunology
Published: September 20, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026